Corporate & Investor Presentation

Q2 FY21 financial results $ in millions, except per share amounts Revenue 2Q21 $800.0 +9% (+7% CC) Non-GAAP gross margin* Non-GAAP operating income* Non-GAAP EPS* 59.9% +20 bps $254.5 +16% * Refer to Non-GAAP reconciliations in the Appendix. 31 © 2021 ResMed | Corporate & Investor Presentation - updated 28JAN21 Diversified revenue by business & by geography OOH SaaS 12% Masks & Other 39% $1.41 +17% Europe, Asia, and Other 35% OOH SaaS 12% Devices 49% Americas Sleep and Respiratory Care 53% ResMed

View entire presentation